DataMeds AI, Inc. 8K

DataMeds AI, Inc. reported Q2 2026 results showing modest revenue growth but a significantly larger loss while executing a major capital, restructuring, rebranding, and partnership program, including a pending Datavault AI transaction and an upcoming Health Lives Here app launch with NFL Alumni Health.

On August 17, 2026, DataMeds AI, Inc. (formerly Wellgistics Health, Inc.; NASDAQ: MEDS) reported its unaudited second quarter 2026 financial results and a broad corporate update, highlighting 14% sequential revenue growth to $1.779 million but a substantially higher net operating loss of $18.363 million driven largely by debt extinguishment and higher general and administrative costs, alongside multiple strategic actions including a $6.5 million capital raise, restructuring of $14.5 million of debt toward a preferred equity swap path, completion of a 1-for-50 reverse stock split to address Nasdaq listing risk, a corporate name and ticker change, entry into a pending Datavault AI-related transaction to consolidate IP and expand its PharmacyChain license, a new KareRx joint venture, lock-up agreements covering ~49% of outstanding shares, the termination of a pending acquisition of Neuritek Therapeutics, the planned September 9, 2026 Dream Bowl Meme Coin I token distribution, and the expected September 2026 launch of its Health Lives Here GLP-1-focused consumer app in partnership with NFL Alumni Health.

Filing Facts

CIK

2030763

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-038891

Alert Tier

7